Why Compass Pathways (CMPS) is a 5-bagger: $210/share

https://youtu.be/lgZbRvQfhPg Grizzle identified Compass Pathways as our conviction call IPO, our primer laid out the opportunity (Sept 18/2020). The stock... Read More»

The Most Anticipated Psychedelic IPO: Compass Pathways (CMPS)

Grizzle sits down with Terry Chong (Partner, Grizzle Ventures) to discuss one of the most anticipated IPOs in the psychedelic sector: Compass Pathways (NASD:CM... Read More»

Psychedelics: Interview with MindMed (MMED) CEO JR Rahn

Grizzle had the pleasure of sitting down with the CEO of MindMed - JR Rahn. Terry Chong leads an in-depth and insightful interview with JR, Terry is a vetera... Read More»

Psychedelics: Valuing MindMed (MMED)

https://youtu.be/umHhVOJd_Yo Thomas George and Terry Chong talk about the process of drug approval and MindMed in the second episode of the Grizzle Psychedel... Read More»

Federal Agency Hosts Discussion on Effects of Psychedelics

The National Institute of Mental Health is bringing in psychedelics expert Dr. Roland Griffiths to give a talk on the neuropharmacology of psilocybin. Griffi... Read More»